These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23008909)

  • 1. FDA remodels REMS for opioid medications.
    Stone A
    ONS Connect; 2012 Sep; 27(9):18. PubMed ID: 23008909
    [No Abstract]   [Full Text] [Related]  

  • 2. REMS; red tape, or a remedy for opioid abuse?
    Porada S
    J Fam Pract; 2011 Sep; 60(9 Suppl):S55-62. PubMed ID: 22442761
    [No Abstract]   [Full Text] [Related]  

  • 3. Opioid risk management: understanding FDA mandated risk evaluation and mitigation strategies (REMS).
    Sloan PA
    J Opioid Manag; 2009; 5(3):131-3. PubMed ID: 19662921
    [No Abstract]   [Full Text] [Related]  

  • 4. Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management.
    Peppin JF; Coleman JJ; Kirsh KL
    Issues Law Med; 2011; 27(2):91-119. PubMed ID: 22372206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evolution of opioid risk management and review of the classwide REMS for extended-release/long-acting opioids.
    Stanos S
    Phys Sportsmed; 2012 Nov; 40(4):12-20. PubMed ID: 23306411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rehabilitating opioid regulation: a prescription for the FDA's next proposal of an opioid risk evaluation and mitigation strategy (REMS).
    Homenko H
    Health Matrix Clevel; 2012; 22(1):273-313. PubMed ID: 22616548
    [No Abstract]   [Full Text] [Related]  

  • 7. Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS).
    Nelson LS; Perrone J
    JAMA; 2012 Aug; 308(5):457-8. PubMed ID: 22851109
    [No Abstract]   [Full Text] [Related]  

  • 8. Narcotic pain relievers: are you using them correctly?
    Johns Hopkins Med Lett Health After 50; 2012 Nov; 24(10):1-2. PubMed ID: 23362527
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA actions to prevent prescription drug abuse.
    Jeske AH
    Tex Dent J; 2005 Jul; 122(7):634-45. PubMed ID: 16152888
    [No Abstract]   [Full Text] [Related]  

  • 10. Extended-release/long-acting opioid REMS may fill the need for prescribers' appropriate use education.
    Nicholson SC; Evanyo K; Salinas GD; Roepke N; Burton BS; Susalka D
    J Opioid Manag; 2012; 8(4):212-6. PubMed ID: 22941848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Shared risk evaluation mitigation strategy for all immediate-release transmucosal fentanyl dosage forms.
    Food And Drug Administration, Public Health Service, U.S. Department Of Health And Human Services
    J Pain Palliat Care Pharmacother; 2012 Jun; 26(2):123-6. PubMed ID: 22764848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marshaling FDA Benefit-Risk Expertise to Address the Current Opioid Abuse Epidemic.
    Gottlieb S; Woodcock J
    JAMA; 2017 Aug; 318(5):421-422. PubMed ID: 28687816
    [No Abstract]   [Full Text] [Related]  

  • 13. Pain treatment agreements.
    Rowe W
    Am J Bioeth; 2010 Nov; 10(11):3-4. PubMed ID: 21104544
    [No Abstract]   [Full Text] [Related]  

  • 14. The FDA's Approach to the Prescription Opioid Problem.
    Woodcock J; Throckmorton DC
    Clin Pharmacol Ther; 2018 Jun; 103(6):954-955. PubMed ID: 29570773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA to propose hydrocodone reclassification.
    J Calif Dent Assoc; 2014 Jan; 42(1):10. PubMed ID: 25080676
    [No Abstract]   [Full Text] [Related]  

  • 16. The Joint Commission and the FDA take steps to curb adverse events related to the use and misuse of opioid drugs.
    ED Manag; 2012 Oct; 24(10):112-6. PubMed ID: 23045763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Food and Drug Administration opioid Risk Evaluation and Mitigation Strategy.
    Lipman AG
    J Pain Palliat Care Pharmacother; 2009; 23(3):219-21. PubMed ID: 19670017
    [No Abstract]   [Full Text] [Related]  

  • 18. The Food and Drug Administration Should Mandate Risk Evaluation and Mitigation Strategies Training for All Opioids.
    Soelberg CD; Chou R; Ramachandran BK; Berkeley A; Brown RE
    Anesth Analg; 2018 Apr; 126(4):1413-1417. PubMed ID: 29547432
    [No Abstract]   [Full Text] [Related]  

  • 19. Wanted: a public health approach to prescription opioid abuse and diversion.
    Joranson DE; Gilson AM
    Pharmacoepidemiol Drug Saf; 2006 Sep; 15(9):632-4. PubMed ID: 16862603
    [No Abstract]   [Full Text] [Related]  

  • 20. Opioid therapy in 2012: a call for a high degree of attention to detail. Introduction.
    de Leon-Casasola OA
    J Pain Symptom Manage; 2012 Dec; 44(6 Suppl):S1-3. PubMed ID: 23218231
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.